

Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA 40211

2: Name of authorisation holder SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED

3: Address(es) of manufacturing site(s) SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9 4NF, UNITED KINGDOM

4: Legally registered address of authorisation holder SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, UNIT 10, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9 4NF, UNITED KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

6: Legal Basis of authorisation Regulation 17 of The Human Medicines Regulations 2012 (SI 2012/1916)

7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation Confidential

8: Authorisation Date 29/11/2024

9: Annexes attached Annex 1 and/or Annex 2

SCOPE OF AUTHORISATION

Annex 1

Name and address of the site:

SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9 4NF, UNITED KINGDOM

Human Medicinal Products
Authorised Operations
MANUFACTURING OPERATIONS (according to part 1) IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)
Part 1 - MANUFACTURING OPERATIONS [1.1] Sterile Products [1.1.1] Aseptically prepared (processing operations for the following dosage forms) [1.1.1.2] Lyophilisates

[1.1.1.4] Small volume liquids

Special Requirements

Cytotoxics

[1.3] Biological medicinal products

[1.3.1] Biological medicinal products

[1.3.1.4] Gene therapy products

[1.3.1.5] Biotechnology products

[1.4] Other products or manufacturing activity

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

Part 2 - IMPORTATION OF MEDICINAL PRODUCTS

[2.2] Batch certification of imported medicinal products

[2.2.3] Biological medicinal products

[2.2.3.4] Gene therapy products

[2.3] Other Importation Activities

[2.3.1] Site of Physical Importation

[2.3.2] Importation of Intermediate which undergoes further processing